Influenza, RSV and SARS-CoV-2 are still the top three viruses to watch out for in the fall and winter, but several public health tools that have become available in the past year should help boost ...
A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. With U.S ...
Merck’s experimental antibody for RSV reduced infants’ risk of certain lower respiratory infections by 60.4% compared to placebo, meeting the trial ...
New real-world data suggests that seniors who get the RSV vaccine have an 80% lower odds for severe illness It's yet another reason to get immunized ahead of another RSV season Widespread immunization ...
Oct. 18, 2024 – Older people who aren’t sure about whether to get the vaccine for respiratory syncytial virus (RSV) now have a new set of data to help them make up their minds. A large study ...
Three months after revealing that its respiratory syncytial virus (RSV) preventive antibody clesrovimab had passed muster in a phase 2b/3 trial, Merck is putting numbers to the claim. Clesrovimab ...
In years prior to the availability of an RSV vaccine, an estimated 60,000 to 160,000 RSV-associated hospitalizations and 6,000 to 10,000 RSV-associated deaths occurred annually among U.S. adults ...
Mr. Quammen is the author of “Breathless: The Scientific Race to Defeat a Deadly Virus.” Health officials would like to remind you that we are entering that time of the year still quaintly ...
What is this silent virus that endangers Filipino Seniors with comorbidities? Respiratory Syncytial Virus (RSV) is not just another cold or flu—it is potentially life- threatening for seniors ...
Respiratory syncytial virus (RSV) causes cold-like symptoms in most people but can cause more serious problems in some, especially babies and older adults. Almost all children get RSV at least once by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback